20 research outputs found

    Relationship between serum hepatitis C virus RNA level and sustained virologic response (SVR).

    No full text
    <p>Short vertical lines indicate the number of patients with SVR (black lines) and no SVR (grey lines). Open circles represent probability of SVR according to the GAM analysis. Closed circles represent empirical probability for midpoints of deciles.</p

    Rapid virologic response (RVR) and sustained virologic response by RVR status in patients with HCV genotype 3 by baseline score.

    No full text
    <p>A) Patients with an RVR; B) Patients without an RVR. RVR = rapid virologic response: HCV RNA <50 IU/mL by week 4 of treatment. <sup>a</sup> Includes patients with missing Week 4 HCV RNA results.</p

    Sustained virologic response by baseline characteristic.

    No full text
    <p>ALT = alanine aminotransferase; ALT ratio = ALT divided by ULN for the local laboratory; ULN = upper limit of normal. P-values are based on univariate regression analysis.</p

    Rate of response in treatment-naive cirrhotic and noncirrhotic Caucasian and patients with HCV genotype 3 by baseline score.

    No full text
    <p>Patients with missing scores omitted (noncirrhotic; n = 48, cirrhotic; n = 11). <sup>a</sup> Patients with missing information on cirrhosis status were given the same score as no cirrhosis.</p

    Enrollment and patient disposition.

    No full text
    <p><sup>a</sup>Other reasons (more than one reason may apply to a given patient): no final confirmation from the investigator (n = 56); contraindications to therapy (n = 15); HCV RNA-negative at screening/baseline (n = 12); end-stage renal disease (n = 7); major organ transplantation (n = 2); not treated with peginterferon alfa (n = 1) or ribavirin (n = 2); acute hepatitis C (n = 1); co-infection with HIV (n = 115); co-infection with HBV (n = 74); treatment with regimen other than peginterferon alfa-2a/ribavirin or peginterferon alfa-2b/ribavirin (n = 14); treatment-naive and intended treatment duration of 72 weeks (n = 6).</p

    Relationship between age and sustained virologic response (SVR).

    No full text
    <p>Short vertical lines indicate the number of patients with SVR (black lines) and no SVR (grey lines). Open circles represent probability of SVR according to the GAM analysis. Closed circles represent empirical probability for midpoints of deciles.</p

    Cox proportional hazards analysis for time to first safety-related dose reductions or discontinuations in patients treated for 24 or 48 weeks with peginterferon alfa-2a or alfa-2b and ribavirin.

    No full text
    <p>(A) All treatment-naive patients (G1ÔÇô6) assigned to 24 or 48 weeks of treatment with peginterferon alfa-2a or alfa-2b/RBV (N = 3181); (B) Subgroup 2: treatment-naive Caucasian, G1 noncirrhotic patients assigned to 48 weeks of treatment with peginterferon alfa-2a/RBV (n = 951).</p
    corecore